10x Genomics completed the acquisition of ReadCoor for $350m.

10x Genomics, an American biotechnology company, completed the acquisition of ReadCoor, a developer of foundational In Situ technologies, from private equity firms Vivo Capital, Lilly Asia Ventures, Decheng Capital and Pavilion Capital Partners for $350m. "Our goal has always been to anticipate the frontiers of biology and build products that accelerate science in exponential ways. We believe that In Situ approaches will be essential for how biological research and clinical assays will be conducted in the future. After a comprehensive assessment of In Situ efforts worldwide, we are thrilled to welcome ReadCoor and CartaNA to the 10x team. Both companies have made significant technical advances, which will serve as a powerful foundation for future product development at 10x. We look forward to joining forces to help our customers make amazing new discoveries to advance human health," Serge Saxonov, 10x Genomics Co-Founder and CEO.